Penny Stock Equillium Falls After Itolizumab Treatment Fails To Show Improvement In Response Rates In Graft Versus Host Disease Patients
1. Equillium's Phase 3 study showed itolizumab did not meet early efficacy benchmarks. 2. Long-term outcomes show significant benefits for itolizumab in aGVHD treatment. 3. Equillium plans to seek Accelerated FDA Approval based on study results. 4. Itolizumab demonstrates favorable safety without increasing serious infection risks. 5. EQ shares fell 33.3%, reflecting market skepticism post-study data release.